Interleukin-12 subunit beta

Description:

Description
  • Accession: P29460
  • Swissprot: IL12B_HUMAN
  • Organism: Homo sapiens
  • Gene: IL12B
  • Target class: Cytokine

Drug Relations:

guselkumab
Guselkumab is a human monoclonal IgG1-lambda antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Guselkumab inhibits the release of proinflammatory cytokines and chemokines. Bioactivity details MOA
tildrakizumab
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines. Bioactivity details MOA
ustekinumab
A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies. Bioactivity details MOA